Education
About Us
Working with TipRanks
Follow Us
INVN - ETF AI Analysis
Top Page
Alger Russell Innovation ETF (INVN)
Rating:72Outperform
Price Target:―
Positive Factors
Innovation-Focused Portfolio
The ETF targets innovative companies in areas like technology and health care, which can benefit from long-term growth trends.
Sector Diversification Within Growth Areas
Holdings are spread across several growth-oriented sectors, so the fund is not tied to just one industry’s fortunes.
Some Strong Individual Stock Performers
A few top holdings have shown strong recent performance, which helps offset weaker names in the portfolio.
Negative Factors
Recent Weak Performance
The ETF has delivered negative returns over the past month, three months, and year-to-date, signaling recent struggles.
High Concentration in Technology and Health Care
Nearly all assets are in technology and health care, which increases risk if these sectors fall out of favor.
Above-Average Expense Ratio for an ETF
The fund’s fee is relatively high for an ETF, which can eat into returns over time, especially when performance is weak.
INVN vs. SPDR S&P 500 ETF (SPY)
AUM11.49M
RegionNorth America
Expense Ratio0.55%
Beta1.02
IssuerAlger
Inception DateJan 07, 2025
Dividend Yield0.31%
Asset ClassEquity
Index TrackedAlger Russell Innovation Index - Benchmark TR Gross
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume5,974
30 Day Avg. Volume3,224
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
25.68Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering50
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
INVN Summary
The Alger Russell Innovation ETF (INVN) tracks the Alger Russell Innovation Index, focusing on large U.S. companies that are leaders in new technologies and medical advances. It holds innovative names like Lyft and Electronic Arts, along with many other tech and health care firms. Someone might invest in this ETF to seek long-term growth by spreading their money across a basket of forward-looking companies instead of picking individual stocks. A key risk is that it is heavily tilted toward technology and health care, so its price can rise and fall sharply with those sectors and the overall stock market.
How much will it cost me?The Alger Russell Innovation ETF (Ticker: INVN) has an expense ratio of 0.55%, which means you’ll pay $5.50 per year for every $1,000 invested. This is higher than average for ETFs because it is actively managed, focusing on innovative large-cap companies rather than tracking a broad index. Active management typically involves higher costs due to research and portfolio adjustments.
What would affect this ETF?The Alger Russell Innovation ETF could benefit from continued advancements in technology and healthcare, as these sectors make up a significant portion of its portfolio and are often drivers of innovation. However, rising interest rates or economic slowdowns may negatively impact growth-focused companies, particularly in consumer cyclical and technology sectors. Regulatory changes or geopolitical tensions in the U.S., where the ETF is primarily focused, could also influence its performance.
INVN Top 10 Holdings
This U.S.-focused innovation ETF leans heavily into tech and health care, and its recent story is a bit of a tug-of-war. Cirrus Logic has been a quiet engine of growth, rising on solid demand and healthy financials, while Organon has surprised to the upside after a strong rebound. On the other side, high-profile names like UiPath, Nutanix, and Bill.com are dragging the fund, with their shares losing steam despite decent revenue trends. Corcept Therapeutics has also been a notable laggard, adding to the fund’s choppy, stock-picking-driven performance.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Lyft | 2.55% | $373.05K | $6.57B | 9.85% | 69 Neutral | |
| Etsy | 2.50% | $366.34K | $5.71B | 1.70% | 57 Neutral | |
| UiPath | 2.41% | $352.68K | $6.89B | -7.66% | 72 Outperform | |
| Electronic Arts | 2.35% | $344.50K | $50.05B | 52.07% | 70 Outperform | |
| Corcept Therapeutics | 2.28% | $334.10K | $4.29B | -38.84% | 76 Outperform | |
| Bill.com Holdings | 2.25% | $329.37K | $4.90B | -21.87% | 74 Outperform | |
| Exelixis | 2.19% | $320.45K | $11.77B | 31.19% | 78 Outperform | |
| Cirrus Logic | 2.17% | $317.48K | $7.28B | 33.76% | 79 Outperform | |
| Nutanix | 2.14% | $314.22K | $10.89B | -42.03% | 62 Neutral | |
| Organon | 2.13% | $311.58K | $2.13B | -47.41% | 53 Neutral |
INVN Technical Analysis
Negative
―
Price Trends
21.31
Negative
21.12
Negative
20.19
Negative
Market Momentum
-0.49
Positive
41.86
Neutral
36.03
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For INVN, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 20.63, equal to the 50-day MA of 21.31, and equal to the 200-day MA of 20.19, indicating a bearish trend. The MACD of -0.49 indicates Positive momentum. The RSI at 41.86 is Neutral, neither overbought nor oversold. The STOCH value of 36.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INVN.
INVN Peer Comparison
Comparison Results
Performance Comparison
INVN
Alger Russell Innovation ETF
20.02
-0.08
-0.40%
BCUS
Bancreek U.S. Large Cap ETF
―
―
―
ALTL
Pacer Lunt Large Cap Alternator ETF
―
―
―
XOEX
Xtrackers S&P 100 Ex Top 20 ETF
―
―
―
LVDS
JPMorgan Fundamental Data Science Large Value ETF
―
―
―
UPSD
Aptus Large Cap Upside ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents